Published in Expert Rev Anticancer Ther on March 13, 2014
SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas. Mol Cancer (2015) 0.77
"Eat me" imaging and therapy. Adv Drug Deliv Rev (2016) 0.77
Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol (2015) 0.77
Characteristics of gastrointestinal hemorrhage associated with pancreatic cancer: A retrospective review of 246 cases. Mol Clin Oncol (2015) 0.76
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res (2000) 2.43
Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer (2007) 1.63
Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS One (2013) 1.61
Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase. J Biol Chem (1994) 1.36
Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res (2009) 1.26
Functional organization of saposin C. Definition of the neurotrophic and acid beta-glucosidase activation regions. J Biol Chem (1996) 1.11
Phospholipid vesicle fusion induced by saposin C. Arch Biochem Biophys (2003) 1.09
Fusogenic domain and lysines in saposin C. Arch Biochem Biophys (2004) 1.09
Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol (2011) 1.08
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther (2013) 1.07
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol (2004) 0.95
Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer (2013) 0.91
Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science (2003) 3.05
Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS One (2013) 1.61
Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc Natl Acad Sci U S A (2007) 1.29
Phospholipid vesicle fusion induced by saposin C. Arch Biochem Biophys (2003) 1.09
Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol (2011) 1.08
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther (2013) 1.07
Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation. J Biol Chem (2003) 1.02
Saposin C-LBPA interaction in late-endosomes/lysosomes. Exp Cell Res (2005) 1.01
Mapping and analysis of the lytic and fusogenic domains of surfactant protein B. Biochemistry (2005) 1.00
Prosaposin: threshold rescue and analysis of the "neuritogenic" region in transgenic mice. Mol Genet Metab (2002) 0.92
Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer (2013) 0.91
Role of lysine residues in membrane anchoring of saposin C. Arch Biochem Biophys (2005) 0.90
Phospholipid membrane interactions of saposin C: in situ atomic force microscopic study. Biophys J (2003) 0.88
Saposin C: neuronal effect and CNS delivery by liposomes. Ann N Y Acad Sci (2005) 0.87
Direct AFM observation of saposin C-induced membrane domains in lipid bilayers: from simple to complex lipid mixtures. Chem Phys Lipids (2004) 0.86
Spontaneously forming ellipsoidal phospholipid unilamellar vesicles and their interactions with helical domains of saposin C. Langmuir (2006) 0.84
Saposins modulate human invariant Natural Killer T cells self-reactivity and facilitate lipid exchange with CD1d molecules during antigen presentation. Proc Natl Acad Sci U S A (2013) 0.83
Structural changes in a binary mixed phospholipid bilayer of DOPG and DOPS upon saposin C interaction at acidic pH utilizing 31P and 2H solid-state NMR spectroscopy. Biochim Biophys Acta (2005) 0.83
Imaging of brain tumors with paramagnetic vesicles targeted to phosphatidylserine. J Magn Reson Imaging (2014) 0.82
Toll-like receptor 4 can recognize SapC-DOPS to stimulate macrophages to express several cytokines. Inflamm Res (2010) 0.82
Investigating the interaction of saposin C with POPS and POPC phospholipids: a solid-state NMR spectroscopic study. Biophys J (2007) 0.80
Controlled release mechanisms of spontaneously forming unilamellar vesicles. Biochim Biophys Acta (2008) 0.78
Computational models for the helix tilt angle. J Chem Inf Comput Sci (2004) 0.76
Brain Tumor Epidemiology - A Hub within Multidisciplinary Neuro-oncology. Report on the 15th Brain Tumor Epidemiology Consortium (BTEC) Annual Meeting, Vienna, 2014. Clin Neuropathol (2014) 0.75
[MicroRNA target predicition based on SVM and the optimized feature set]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi (2013) 0.75